Cornelius to retire as Bristol-Myers Squibb CEO

Former Guidant Corp. CEO James M. Cornelius has announced his retirement as chief executive of drugmaker Bristol-Myers Squibb
Co., the company announced Tuesday.

The Trenton, N.J.-based company's board chose Lamberto Andreotti, 59, to replace Cornelius as CEO effective May 4. Cornelius,
66, will remain as Bristol's chairman. Andreotti has been Bristol's president and chief operating officer since March
2009.

Cornelius became Bristol's chairman in February 2008 after being elected CEO by the board of directors in April 2007.
That was after he had served as interim CEO for about eight months.

"I said before I was a reluctant CEO," this time, Cornelius said Tuesday during a conference call. "I truly
didn't have any aspirations to become a CEO" again and had to "convince my wife to move from Indianapolis to
New York."

Yet, just five weeks ago, during a conference call announcing fourth quarter results, Cornelius told analysts asking about
succession planning that he didn't intend to retire soon because he was still enjoying the job. He said he and his family
are still discussing what's next, but that they will be moving back to Indianapolis.

Cornelius previously served as chief financial officer at Indianapolis-based Eli Lilly and Co., where he worked for nearly
three decades before first "retiring" in 1995. He then retired twice from medical device maker Guidant Corp., in
2000 and again in 2006.

Cornelius served as chairman emeritus of the Guidant board of directors when it closed its merger into Boston Scientific
in April 2006. Previously, he had been chairman and CEO during the merger process and was responsible for the company's
initial public offering and subsequent split-off from Eli Lilly in 1995.

Prior to his role at Guidant, Cornelius was Lilly's CFO from 1983 to 1995. From 1980 to 1982, he was CEO of former Lilly
subsidiary IVAC Corp.

During his time at the helm of Bristol-Myers, Cornelius initiated a strategy dubbed the "String of Pearls" to sell
off noncore businesses such as its Mead Johnson nutrition franchise and buy multiple pearls , biotech companies or products
in development , to transform the company into a biopharmaceutical powerhouse.

Andreotti said the company already has completed nine such deals.

The most prominent was last summer's $2.1 billion purchase of biotech company Medarex Inc. It owns successful antibody
technology used to create biologic drugs that make the immune system attack cancer cells , and it has several of its own drugs
in development.

Most of Bristol's competitors instead have been focused on diversifying their product lines and slashing costs.

Bristol-Myers is the maker of blood thinner Plavix, the world's second-best-selling drug.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}